Wall Street brokerages expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings per share (EPS) of ($1.26) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Eiger BioPharmaceuticals’ earnings. The lowest EPS estimate is ($1.39) and the highest is ($1.04). Eiger BioPharmaceuticals posted earnings of ($1.49) per share in the same quarter last year, which suggests a positive year over year growth rate of 15.4%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 14th.

On average, analysts expect that Eiger BioPharmaceuticals will report full-year earnings of ($5.41) per share for the current fiscal year, with EPS estimates ranging from ($5.52) to ($5.22). For the next financial year, analysts forecast that the firm will post earnings of ($5.16) per share, with EPS estimates ranging from ($5.86) to ($4.78). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.28) by $0.05.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. Piper Jaffray Companies restated a “buy” rating and set a $36.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Tuesday, August 15th. Wedbush restated an “ourperform” rating and set a $34.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Monday, August 14th. BTIG Research initiated coverage on Eiger BioPharmaceuticals in a research note on Friday, July 14th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. set a $34.00 price objective on Eiger BioPharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, June 8th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $28.46.

A number of hedge funds have recently modified their holdings of EIGR. Hikari Power Ltd raised its stake in shares of Eiger BioPharmaceuticals by 491.0% in the second quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 50,672 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter valued at approximately $272,000. LMR Partners LLP acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter valued at approximately $116,000. Susquehanna International Group LLP acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter valued at approximately $114,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Eiger BioPharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 871 shares during the last quarter. 59.94% of the stock is currently owned by institutional investors.

Shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) traded up 0.238% on Monday, hitting $8.019. 2,642 shares of the stock were exchanged. The company has a 50 day moving average of $8.43 and a 200 day moving average of $8.80. The company’s market cap is $67.09 million. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $16.80.

ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/28/1-26-earnings-per-share-expected-for-eiger-biopharmaceuticals-inc-eigr-this-quarter.html.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Get a free copy of the Zacks research report on Eiger BioPharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.